Menu
Search
|

Menu

Close
X

Caladrius Biosciences Inc CLBS.OQ (NASDAQ Stock Exchange Capital Market)

5.72 USD
+0.12 (+2.14%)
As of 1:30 AM IST
chart
Previous Close 5.60
Open 5.65
Volume 14,047
3m Avg Volume 50,725
Today’s High 5.92
Today’s Low 5.65
52 Week High 11.65
52 Week Low 2.65
Shares Outstanding (mil) 8.91
Market Capitalization (mil) 32.35
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
22
EPS (USD)
FY18
-0.521
FY17
1.373
FY16
-4.930
FY15
-16.888
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
1.66
5.73
Price to Book (MRQ)
vs sector
0.59
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
1.11
16.72
LT Debt to Equity (MRQ)
vs sector
0.04
12.39
Return on Investment (TTM)
vs sector
-47.46
14.61
Return on Equity (TTM)
vs sector
-70.71
16.34

EXECUTIVE LEADERSHIP

David Mazzo
Chief Executive Officer, Independent Director, Since 2015
Salary: $541,371.00
Bonus: --
Joseph Talamo
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $261,932.00
Bonus: --
Douglas Losordo
Chief Medical Officer, Since 2013
Salary: $405,000.00
Bonus: --
Gregory Brown
Director, Since 2016
Salary: --
Bonus: --
Richard Berman
Independent Director, Since 2006
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

110 Allen Rd
BASKING RIDGE   NJ   07920-4500

Phone: +1908.8420100

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

SPONSORED STORIES